Calidi Biotherapeutics Appoints New Chief Medical Officer

Calidi Biotherapeutics ( (CLDI) ) just unveiled an update.

On April 10, 2025, Calidi Biotherapeutics announced the appointment of Dr. Guy Travis Clifton as Chief Medical Officer, Consultant, and Advisor. Dr. Clifton, a seasoned surgical oncologist with extensive experience in drug development and cancer immunotherapy, will provide medical and scientific expertise to advance Calidi’s clinical programs. His appointment is expected to bolster the company’s efforts in developing its stem cell-based and enveloped virus platforms, potentially transforming cancer treatment.

Spark’s Take on CLDI Stock

According to Spark, TipRanks’ AI Analyst, CLDI is a Underperform.

Calidi Biotherapeutics presents a high-risk investment with financial instability and technical weakness. While recent corporate developments offer some optimism, the company’s lack of revenue and profitability, combined with bearish technical indicators, weigh heavily on its overall stock score.

To see Spark’s full report on CLDI stock, click here.

More about Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing targeted antitumor virotherapies. The company utilizes proprietary stem cell-based platforms to enhance the efficacy and safety of oncolytic viruses for treating various oncology indications, including high-grade gliomas and solid tumors. Headquartered in San Diego, California, Calidi aims to transform cancer treatment through its innovative approaches.

YTD Price Performance: -63.73%

Average Trading Volume: 1,297,771

Technical Sentiment Signal: Strong Buy

Current Market Cap: $14.38M

For a thorough assessment of CLDI stock, go to TipRanks’ Stock Analysis page.